BPTH (Bio-Path Holdings) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 09, 2026)


What is Bio-Path Holdings 5-Year Yield-on-Cost %?

Bio-Path Holdings BPTH +5.26% 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. The stock has 1 warning sign investors should review. Among 153 Biotechnology companies, Bio-Path Holdings ranks worse than 653594.12% on this metric.

Bio-Path Holdings's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Bio-Path Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:



BPTH's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.66
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Bio-Path Holdings  (OTCPK:BPTH) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Bio-Path Holdings 5-Year Yield-on-Cost % Related Terms

BPTH vs VBIO, HEPA, AXIM: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Bio-Path Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's 5-Year Yield-on-Cost % falls into.


Bio-Path Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Bio-Path Holdings is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Bio-Path Holdings (BPTH) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bio-Path Holdings and its competitors. According to the industry distribution chart, Bio-Path Holdings ranks #999999 out of 153 companies in the Biotechnology industry.
Is Bio-Path Holdings' 5-Year Yield-on-Cost % too high?
Bio-Path Holdings' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Bio-Path Holdings ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Path Holdings' 5-Year Yield-on-Cost % compare to VBIO and HEPA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Bio-Path Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.66, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bio-Path Holdings and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Path Holdings's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.